<p>，/PRNewswire/ -- Kessler Topaz Meltzer &amp; Check, LLP（www.ktmc.com）目前正在代表 uniQure N.V.（NASDAQ: QURE）（&#34;uniQure&#34;）的投资者调查潜在的联邦证券法违规行为。</p>
<p>2025 年 11 月 3 日，uniQure 发布新闻稿，透露 FDA 通知公司其 AMT-130（用于亨廷顿舞蹈症的实验性基因疗法）的数据未能提供足够的证据以支持 uniQure 的生物制品许可申请（&#34;BLA&#34;）提交。具体而言，uniQure 披露公司认为 FDA 目前不再同意 AMT-130 的 I/II 期研究数据可能足以作为 BLA 提交的主要证据，并且由于这一原因，AMT-130 的 BLA 提交时间现在变得不明确。</p>
<p>在这一消息发布后，uniQure 的股价下跌超过 50%，从 2025 年 10 月 31 日的收盘价 67.69 美元跌至 2025 年 11 月 3 日的收盘价 34.29 美元。</p>
<p><strong><em>如果您是 uniQure 的投资者并希望了解更多关于我们调查的信息，请点击此处填写我们的在线表格或联系 Kessler Topaz Meltzer &amp; Check, LLP：Jonathan Naji, Esq. (484) 270-1453 或通过电子邮件联系 [email protected].</em></strong> <strong><em>您也可以点击以下链接或将其粘贴到您的浏览器中：</em></strong> https://www.ktmc.com/uniqure-nv-investigation?utm_source=PR_Newswire&amp;mktm=PR</p>
<p>Kessler Topaz Meltzer &amp; Check, LLP（KTMC）是一家领先的美国原告方律师事务所，专注于证券欺诈集体诉讼和全球投资者保护。该事务所代表个人投资者以及机构，如主要养老金基金、资产管理公司和国际投资者。KTMC 在证券诉讼中主导了一些最大的赔偿案件，并获得同行和法律媒体的众多荣誉，包括《国家法律杂志》的原告热门名单和原告法律的开拓者、BTI 咨询集团的最令人畏惧律师事务所荣誉榜、《法律智库》的年度集体诉讼律师事务所、Lawdragon 的领先原告金融律师以及 Law360 的原告律师行业巨头。该事务所在宾夕法尼亚州和加利福尼亚州设有办事处，业务遍及全球。有关 Kessler Topaz Meltzer &amp; Check, LLP 的更多信息，请访问 www.ktmc.com。</p>
<p><strong>联系方式：</strong> Kessler Topaz Meltzer &amp; Check, LLP</p>
<p>Jonathan Naji, Esq.</p>
<p>280 King of Prussia Road</p>
<p>Radnor, PA 19087</p>
<p>(484) 270-1453</p>
<p>[email protected]</p>
<p>在某些司法管辖区可能被视为律师广告。过去的结果并不保证未来的结果。</p>
<p>来源 Kessler Topaz Meltzer &amp; Check, LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjI5Jk5ld3NJdGVtSWQ9REM1NDUyMiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMjkyMTQwUFJfTkVXU19VU1BSX19fX19EQzU0NTIy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjI5Jk5ld3NJdGVtSWQ9REM1NDUyMiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMjkyMTQwUFJfTkVXU19VU1BSX19fX19EQzU0NTIy"/></p>

QURE

<p>Kessler Topaz Meltzer & Check, LLP 正在代表 uniQure N.V. (NASDAQ: QURE) 的投资者调查潜在的联邦证券法违规行为。在 2025 年 11 月 3 日的一份新闻稿中，uniQure 透露 FDA 认为其 AMT-130 基因疗法的数据不足以支持生物制品许可申请，导致股价下跌超过 50%。遭受重大损失的投资者被鼓励联系该公司以获取更多信息</p>

<p>, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer &amp; Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (&#34;uniQure&#34;).</p>
<div class="lb-trans"><p>，/PRNewswire/ -- Kessler Topaz Meltzer &amp; Check, LLP（www.ktmc.com）目前正在代表 uniQure N.V.（NASDAQ: QURE）（&#34;uniQure&#34;）的投资者调查潜在的联邦证券法违规行为。</p>
</div><p>On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application (&#34;BLA&#34;) submission. Specifically, uniQure disclosed that the company believes the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate to provide the primary evidence in support of a BLA submission, and that the timing of the BLA submission for AMT-130 is now unclear as a result.</p>
<div class="lb-trans"><p>2025 年 11 月 3 日，uniQure 发布新闻稿，透露 FDA 通知公司其 AMT-130（用于亨廷顿舞蹈症的实验性基因疗法）的数据未能提供足够的证据以支持 uniQure 的生物制品许可申请（&#34;BLA&#34;）提交。具体而言，uniQure 披露公司认为 FDA 目前不再同意 AMT-130 的 I/II 期研究数据可能足以作为 BLA 提交的主要证据，并且由于这一原因，AMT-130 的 BLA 提交时间现在变得不明确。</p>
</div><p>On this news, the price of uniQure's stock fell over 50%, from a close of $67.69 on October 31, 2025, to close at $34.29 on November 3, 2025.</p>
<div class="lb-trans"><p>在这一消息发布后，uniQure 的股价下跌超过 50%，从 2025 年 10 月 31 日的收盘价 67.69 美元跌至 2025 年 11 月 3 日的收盘价 34.29 美元。</p>
</div><p><strong><em>If you are a uniQure investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer &amp; Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at [email protected].</em></strong> <strong><em>You can also click on the following link or paste it in your browser:</em></strong> https://www.ktmc.com/uniqure-nv-investigation?utm_source=PR_Newswire&amp;mktm=PR</p>
<div class="lb-trans"><p><strong><em>如果您是 uniQure 的投资者并希望了解更多关于我们调查的信息，请点击此处填写我们的在线表格或联系 Kessler Topaz Meltzer &amp; Check, LLP：Jonathan Naji, Esq. (484) 270-1453 或通过电子邮件联系 [email protected].</em></strong> <strong><em>您也可以点击以下链接或将其粘贴到您的浏览器中：</em></strong> https://www.ktmc.com/uniqure-nv-investigation?utm_source=PR_Newswire&amp;mktm=PR</p>
</div><p>Kessler Topaz Meltzer &amp; Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. For more information about Kessler Topaz Meltzer &amp; Check, LLP, please visit www.ktmc.com.</p>
<div class="lb-trans"><p>Kessler Topaz Meltzer &amp; Check, LLP（KTMC）是一家领先的美国原告方律师事务所，专注于证券欺诈集体诉讼和全球投资者保护。该事务所代表个人投资者以及机构，如主要养老金基金、资产管理公司和国际投资者。KTMC 在证券诉讼中主导了一些最大的赔偿案件，并获得同行和法律媒体的众多荣誉，包括《国家法律杂志》的原告热门名单和原告法律的开拓者、BTI 咨询集团的最令人畏惧律师事务所荣誉榜、《法律智库》的年度集体诉讼律师事务所、Lawdragon 的领先原告金融律师以及 Law360 的原告律师行业巨头。该事务所在宾夕法尼亚州和加利福尼亚州设有办事处，业务遍及全球。有关 Kessler Topaz Meltzer &amp; Check, LLP 的更多信息，请访问 www.ktmc.com。</p>
</div><p><strong>CONTACT:</strong> Kessler Topaz Meltzer &amp; Check, LLP</p>
<div class="lb-trans"><p><strong>联系方式：</strong> Kessler Topaz Meltzer &amp; Check, LLP</p>
</div><p>Jonathan Naji, Esq.</p>
<div class="lb-trans"><p>Jonathan Naji, Esq.</p>
</div><p>280 King of Prussia Road</p>
<div class="lb-trans"><p>280 King of Prussia Road</p>
</div><p>Radnor, PA 19087</p>
<div class="lb-trans"><p>Radnor, PA 19087</p>
</div><p>(484) 270-1453</p>
<div class="lb-trans"><p>(484) 270-1453</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.</p>
<div class="lb-trans"><p>在某些司法管辖区可能被视为律师广告。过去的结果并不保证未来的结果。</p>
</div><p>SOURCE Kessler Topaz Meltzer &amp; Check, LLP</p>
<div class="lb-trans"><p>来源 Kessler Topaz Meltzer &amp; Check, LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjI5Jk5ld3NJdGVtSWQ9REM1NDUyMiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMjkyMTQwUFJfTkVXU19VU1BSX19fX19EQzU0NTIy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC54522&amp;Transmission_Id=202512292140PR_NEWS_USPR_____DC54522&amp;DateId=20251229"/></p>

21:40 ET
			
			
				QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

QURE 调查通知：Kessler Topaz Meltzer & Check, LLP 鼓励在 Uniqure N.V.（NASDAQ: QURE）遭受重大损失的投资者与该公司联系